Green tea compound tested for lung scarring disease

NCT ID NCT05195918

Completed Disease control Sponsor: Hal Chapman Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a purified green tea extract called EGCG in 50 people with idiopathic pulmonary fibrosis (IPF) who were already taking standard medications. The main goal was to check if EGCG is safe and how it interacts with their usual drugs. Participants took EGCG or a placebo daily for 12 weeks, and researchers monitored side effects, lung function, and drug levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EGCG (epigallocatechin-3-gallate), a purified green tea extract
What this could lead to: If safe and effective, EGCG could become an add-on treatment to help control idiopathic pulmonary fibrosis.
What could go wrong: This is an early Phase 1 safety study with only 50 participants, so it cannot prove whether EGCG actually helps IPF. It may also interact with standard IPF medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Temple University

Philadelphia, Pennsylvania, 19140, United States
UCSF Parnassus

San Francisco, California, 94143, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Virginia

Charlottesville, Virginia, 22908, United States
University of Washington

Seattle, Washington, 98195, United States
Weill Cornell Medicine

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.